Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential ...

IMUNON's PlaCCine® platform shows advantages over mRNA vaccines, demonstrating durability and safety in a Phase 1 COVID-19 trial. IMUNON, Inc. announced promising results from its Phase 1 ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

“IMUNON continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered ...

Analysts estimate that Imunon will report an earnings per share (EPS) of $-0.36. Investors in Imunon are eagerly awaiting the ...

Application error: a client-side exception has occurred (see the browser console for more information).

In the Phase 1 trial, designed to demonstrate the advantages of IMUNON’s technology compared to approved messenger RNA (mRNA) vaccines, IMNN-101 was administered as a single dose vaccine without ...